Loading organizations...
Key people at Bio-Rad Laboratories.
Bio-Rad Laboratories is a publicly traded developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets, based in Hercules, California. Trading on the New York Stock Exchange under the ticker BIO, the corporation operates globally with approximately 7,500 employees and generated $2.6 billion in annual sales during the 2024 fiscal year. Its extensive hardware and software portfolio features laboratory instruments, chromatography media, and electrophoresis equipment, highlighted by the QX600 Droplet Digital PCR System built upon technology acquired from QuantaLife. Under the leadership of Chief Executive Officer Norman Schwartz, the enterprise supplies academic research institutions, public health laboratories, and biotechnology companies with essential tools to accelerate drug development and medical testing. The global organization Bio-Rad Laboratories was originally founded in the year 1952 by David Schwartz and Alice Schwartz.
Key people at Bio-Rad Laboratories.
Bio-Rad Laboratories is an American developer and manufacturer of specialized technological products for life science research and clinical diagnostics markets, headquartered in Hercules, California.[1][5] Founded in 1952, the company provides tools like ion exchange resins, gel electrophoresis systems, PCR technologies, and diagnostic tests for applications in gene expression studies, drug discovery, hemoglobin disorder screening, autoimmune disease detection, and quality control solutions, serving researchers, clinicians, hospitals, universities, biotech firms, and pharmaceutical companies worldwide.[1][2][4][5] With annual sales of $2.6 billion in 2024 and approximately 7,500 employees as of June 2025, Bio-Rad maintains strong growth through innovations like droplet digital PCR and acquisitions enhancing its portfolio in biopharma and molecular diagnostics.[3][5]
Bio-Rad Laboratories was founded in 1952 in a small Quonset hut in Berkeley, California, by husband-and-wife team David Schwartz (UC Berkeley graduate) and Alice Schwartz (UC Berkeley biochemistry bachelor's), who aimed to accelerate scientific discovery with early products like ion exchange resins and tools for protein purification and analysis.[1][2][4][6] The company incorporated in 1957, relocated to Richmond in 1958, went public in 1966 raising $140,000 with its first international office in Munich, and entered diagnostics in 1967 with revolutionary T-4 thyroid and lead poisoning tests.[2][3][4] Key milestones include listing on the American Stock Exchange in 1980, introducing gel electrophoresis in 1969, hemoglobin A1c tests in the 1980s, real-time PCR in 1998, a mad cow disease test in 2000, and droplet digital PCR in 2011 via acquisition; Norman Schwartz became CEO in 2003, continuing family leadership.[1][2][3]
Bio-Rad stands out in life sciences and diagnostics through decades-honed expertise in separation technologies, precision instrumentation, and quality control:
Bio-Rad rides key trends in genomics, personalized medicine, and biopharma acceleration, providing essential tools for DNA analysis, protein purification, and precise diagnostics amid rising demands for faster drug discovery, food safety testing, and chronic disease management.[1][4][5] Its timing aligns with post-2000 biotech booms, from mad cow safeguards to PCR advancements enabling tumor sequencing and vaccine development, influencing ecosystems by equipping 21st-century labs—from university classrooms to global pharma—with scalable, reliable solutions that unlock genetic insights and ensure diagnostic accuracy.[2][3][5] Market forces like aging populations boosting diabetes/autoimmune testing and regulatory needs for quality controls favor Bio-Rad's established leadership, while its tech underpins broader advances in synthetic biology and precision health.[4][5]
Bio-Rad is poised for expansion in high-growth areas like next-gen sequencing integration, AI-enhanced diagnostics, and bioprocessing for cell/gene therapies, building on its Droplet Digital PCR and quality control dominance to capture shares in a $100B+ life sciences market.[5] Trends such as personalized medicine, global health threats, and sustainable biomanufacturing will shape its path, with potential for strategic acquisitions and ERP optimizations driving efficiency. Its influence may evolve from toolmaker to ecosystem enabler, deepening impacts on scientific breakthroughs and healthcare as it sustains the innovative spirit ignited in that 1952 Berkeley hut.[2][5]
